Pure Global
NCT06419348

99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer

99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET
First Affiliated Hospital of Chongqing Medical University·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Prostate Cancer Stage,PSMA,SPECT
Drug/Device/Intervention
99mTc-QULIC-5-P1
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
First Affiliated Hospital of Chongqing Medical University
Location
Chongqing, China
Timeline & enrollment
Phase
Phase 1
Start date
May 20, 2024
End date
Dec 31, 2026
Enrollment
30 participants
Primary outcome

Diagnostic efficacy

Summary

99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent
 imaging agent applicable to PSMA positive prostate cancer. In this study, we will investigate
 the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for
 the diagnosis of lesions in PSMA positive prostate cancer.

ICD-10 classifications
Malignant neoplasm of prostateSpecial screening examination for neoplasm of prostateHyperplasia of prostateCarcinoma in situ: ProstateBenign neoplasm: Prostate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06419348
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06419348 through Pure Global AI's free database. This Phase 1 trial is sponsored by First Affiliated Hospital of Chongqing Medical University and is currently Not yet recruiting. The study focuses on Prostate Cancer Stage,PSMA,SPECT. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.